SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1

Author:

Wang Qian12,Guo Yicheng1,Schwanz Logan T.3,Mellis Ian A.14,Sun Yiwei5,Qu Yiming6,Urtecho Guillaume6,Valdez Riccardo7,Stoneman Emily8,Gordon Aubree9,Wang Harris H.6,Ho David D.121011,Liu Lihong1101213

Affiliation:

1. Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

2. Pandemic Research Alliance unit at the Wu Family Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

3. Department of Pathobiology and Mechanisms of Disease, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

4. Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

5. Department of Biomedical Informatics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

6. Department of Systems Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

7. Department of Pathology, University of Michigan, Ann Arbor, MI, USA

8. Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

9. Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA

10. Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

11. Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

12. State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, People’s Republic of China

13. Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, People’s Republic of China

Funder

Bill and Melinda Gates Foundation

National Science Foundation

National Institutes of Health

Publisher

Informa UK Limited

Reference9 articles.

1. CDC. CDC Tracks New SARS-CoV-2 Variant BA.2.87.1. 2024 [cited; Available from: https://www.cdc.gov/ncird/whats-new/covid-19-variant-update-2024-02-09.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Frespiratory-viruses%2Fwhats-new%2Fcovid-19-variant-update-2024-02-09.html.

2. Gisaid's role in pandemic response;Khare S;China CDC Wkly,2021

3. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1;Wang Q;Cell Host Microbe,2024

4. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

5. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies;Kubik S;Viruses,2024

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3